A clinician with a question about your therapy no longer reaches for the label. They open ChatGPT, or Perplexity, or a medical answer engine like OpenEvidence, and they type the question in plain language. The machine answers in a sentence or two, fluent and confident. That sentence was assembled from your label, somebody else's summary of your trial, a years-old abstract, and whatever the model inferred to fill the gaps. Nobody at your company wrote it, nobody reviewed it, and it is being spoken thousands of times a week. A 2024 Wolters Kluwer survey found that a clear majority of physicians expect generative AI to change how they practice, and adoption is running ahead of any policy that governs it (Source: Wolters Kluwer, 2024). The exposure that creates is the one almost no brand is measuring: AI off-label pharma risk, generated by the model, attached to your name, and invisible to the people accountable for the message.
This is not a future problem to budget for in 2027. It is happening in the present tense, and it is compounding, because every brand that says nothing leaves the machine to assemble an answer from material the brand never approved. The uncomfortable part is that the off-label reading is not a malfunction. It is the model doing exactly what it was built to do.
The mechanism is retrieval plus summarization, and both betray the label
To see why your approved message goes off-label in a machine answer, you have to look at how the answer is actually built. There are two steps, and each one works against you.
The first is retrieval. When a clinician asks about a drug, the engine pulls sources: your label if it can find it cleanly, but also press coverage, formulary notes, patient forums, competitor comparisons, and summaries of trials that have since been superseded. The model does not weight these the way your regulatory team would. It weights them for relevance and fluency. A tidy third-party summary that skipped the safety section can easily outrank your dense, caveated, MLR-approved language, because the summary is easier to lift.
The second step is summarization, and this is where the damage is done. Your approved claim was engineered so that every clause survives scrutiny: the indication is bounded, the population is specified, the contraindication sits right next to the benefit. The model was engineered to be concise and fluent, which means to drop clauses. It paraphrases. It compresses three sentences into one. In doing so it routinely drops the qualifier, generalizes the indication, or omits the contraindication, because those clauses read, to a summarizer, like detail it can spare. Fluency and fidelity are in direct tension, and the model resolves that tension in favor of fluency every single time. That is the GenAI pharma compliance risk in one line: the same mechanism that makes the answer useful is the mechanism that makes it off-label.
Saying nothing does not buy you silence. It buys you a confident wrong answer
There is a comfortable assumption inside a lot of brand teams that if you have not engaged with these tools, you are not exposed to them. The opposite is true. A brand that has never said a word in the machine's vocabulary does not get silence when someone asks about it. It gets an answer, assembled from whatever ambient content was lying around: the old abstract, the patient forum thread, the competitor's framing of your data. The model fills the gap, and it fills it confidently, because confidence is a property of the writing style, not of the evidence behind it.
So the choice was never between engaging and staying neutral. There is no neutral. When you stay quiet, you are not declining to participate. You are delegating your label summary to the internet and to a model's inference, and accepting whatever they produce. That is the part that makes AI misinformation pharma a board-level concern rather than a marketing curiosity: the misinformation is generated freshly, per user, on your behalf, and you have no copy of what was said.
A worked example: what the machine says about Varigel, before and after
Take a fictional brand, Varigel, approved for a single narrow indication, with a known contraindication in patients on a common comorbidity medication. The label is precise. The MLR file is immaculate. The approved sentence reads, in effect: Varigel is indicated for the approved condition in the specified population, and is contraindicated in patients taking the comorbidity medication.
Now ask three engines, in a clinician's plain phrasing, what Varigel is used for.
The first answers cleanly and points to the label. This is the outcome you want, and it is the one you cannot count on.
The second describes Varigel for its approved indication and then adds, in a confident aside, a "commonly discussed" second use that traces back to a conference abstract from years ago that the brand never promoted. The model did not flag it as exploratory. It read it as established. That is off-label drift, generated and unprompted, sitting in an answer a prescriber just took at face value.
The third gives a crisp, helpful summary of the efficacy data and never mentions the contraindication, because the source it leaned on summarized the benefit and skipped the safety section. The omission is not visible in the answer. It looks complete. It is the most dangerous of the three precisely because nothing in it signals that something is missing.
Here is the question every brand should be able to answer and almost none can. Across the engines your audience actually uses, how often does each of those three things happen this week, and did it get better or worse after your last data readout? This is the ChatGPT pharma off-label question made concrete, and without an instrument pointed at the machine, the honest answer is that you are guessing, in writing, about a regulatory exposure you cannot see.
No internal function owns this, which is why it stays invisible
The reason the drift compounds is not negligence. It is an org-chart hole. MLR governs what you publish. Medical affairs governs the evidence. Brand governs the campaign. None of them has a mandate over what a third-party model says about the drug when no human from your company is in the room. The machine answer falls into the gap between three functions, and a gap is exactly where nothing gets measured.
So when an off-label reading appears, it is found late, by accident, usually in a screenshot a field rep or a medical science liaison forwards in alarm after a clinician quoted it back to them. By then the answer has been spoken for months. The instinct is to treat it as a one-off and move on. It is not a one-off. It is a steady-state output of a system nobody is watching, and the next model update can change it again without warning. Treating AI off-label pharma exposure as an incident, rather than a surface to monitor, is the second mistake, and it follows directly from the first.
Three moves every brand should make now
You do not need a moonshot. You need to treat the machine's answer as a measurable surface and put three things in place.
1. Take the baseline before you do anything else. Pick the twenty questions your HCPs and patients actually ask, in their words, not your campaign headlines. Run them across the engines your audience uses: ChatGPT, Gemini, Perplexity, Google AI Overviews, and the medical answer engines in your therapeutic area. Record three things per answer: are you mentioned, does the mention match the label, and does anything read off-label. That is your exposure, in numbers, for the first time.
2. Trace every off-label reading back to a source. A drift you cannot source is a drift you cannot fix. For each off-label or omitted-safety answer, find what the model leaned on: the stale abstract, the third-party summary, the gap your own content left open. Sourcing the drift turns a vague anxiety into a work item somebody can actually close, and it tells you whether the fix is to publish a cleaner approved source or to correct something already in the wild.
3. Watch it continuously and route it back to MLR. A baseline taken once is a screenshot of a river. When a model updates, when a competitor publishes, when a new abstract surfaces, the answer moves. The brands that get ahead of this will detect a new off-label reading the week it appears, trace it to its source, and route it to the people who own the underlying content, so the correction lands in the system of record and not in a panicked email thread.
Where this leaves you
The reason most brands cannot run those three moves is that the inside and the outside have never been connected. The team that approves the message has no view of what the machine says. Whoever might watch the machine has no authority over the approved message. So drift is found late, sourced never, and corrected by accident.
Juncture is built for that seam. Inside, it pre-checks the approved message before MLR, comparing every asset against the label, surfacing how much of it reuses already-approved content, and backing the reviewer with a 21 CFR Part 11 trail and an e-signature sign-off. Outside, its Answer Monitor measures Share of Answer and detects off-label drift across the engines your audience uses, continuously, and it traces each drift back to the label clause it violated. The value is the join. Because Juncture already holds the approved sentence you cleared on the inside, it can see a machine answer not as a free-floating paragraph but as a deviation from a known-good source, which off-label reading, which dropped qualifier, which missing contraindication, measured against the exact clause that should have been there. Content reuse is the tangible payoff that funds the rest: you approve faster, you ship more from a smaller approved core, and the thing you ship is the thing the machine learns to repeat.
The off-label answer is already out there. The only question is whether you see it as a deviation from a sentence you control, or hear about it in a screenshot after a prescriber has already read it.
Bring one brand and the twenty questions your audience actually asks. We will show you what the machine says about it today, flag the off-label drift already in the wild, and trace each one back to the approved clause it broke. See it on your brand, then decide.